¿Cómo paga?

Cómo pagar lo menos posible

Lo administra su equipo médico

Lo factura la clínica

Enhertu lo administra un médico o una enfermera; no se recoge en una farmacia.

Qué hacer

  1. Antes de su cita, pregunte a su equipo médico o a su plan cuánto pagaría.

Su equipo médico y su seguro deciden qué producto recibe.

Compare todas las opciones

De marca

Enhertu, el original

Sin seguroPregunte en la farmacia
Formas de ahorrar en Enhertu

La tarjeta del fabricante

ENHERTU Patient Savings Program (ENHERTU4U)

Tarjeta de ahorro de Daiichi Sankyo

Sin seguroRequiere seguroNo tiene precio sin seguro.
Con seguro · desde $0 al año

Inscríbase en enhertu4u.com 

O llame al 1-833-904-1851.

En palabras del fabricante (en inglés)

“Eligible patients may pay as little as $0 per year for ENHERTU out-of-pocket costs.”

De la oferta del fabricante en enhertu4u.com, revisada el 27 de octubre de 2026. Las tarjetas de copago no se pueden usar con Medicare (incluido Medicare Advantage), Medicaid, TRICARE ni VA.

Genérico autorizado

No existe ninguno.

No se vendeNo existe ninguno

Genérico regular

Enhertu es un medicamento biológico. Los biológicos no tienen genéricos, pero algunos tienen biosimilares o una versión sin marca del mismo fabricante. Pregúntele a su farmacéutico o a su médico si se vende alguno.

No se vendePregunte en la farmacia

Para qué se usa

Lo que dice la etiqueta de la FDA (en inglés)

ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for:

HER2-Positive Early Breast Cancer

  • as neoadjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer, as determined by an FDA-authorized test followed by a taxane, trastuzumab, and pertuzumab (THP).
  • as adjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) breast cancer who have residual invasive disease following neoadjuvant trastuzumab (with or without pertuzumab) and taxane-based treatment.

HER2-Positive Metastatic Breast Cancer

  • in combination with pertuzumab as first-line treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer, as determined by an FDA-authorized test.
  • as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or, in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.

HER2-Low and HER2-Ultralow Metastatic Breast Cancer

  • as monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-authorized test, that has progressed on one or more endocrine therapies in the metastatic setting.
  • as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-authorized test, who have received a prior chemotherapy in the metastatic setting; or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.

HER2-Mutant Unresectable or Metastatic Non-Small Cell Lung Cancer

  • as monotherapy for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-authorized test, and who have received a prior systemic therapy*

HER2-Positive Locally Advanced or Metastatic Gastric Cancer

  • as monotherapy for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.

HER2-Positive (IHC 3+) Unresectable or Metastatic Solid Tumors

  • as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options*
  • These indications are approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Fuente: la etiqueta de la FDA de Enhertu (Daiichi Sankyo Inc.), 15 de mayo de 2026. Etiqueta completa en DailyMed 

Datos útiles

  • “Seguro comercial” quiere decir un plan de su trabajo, del Mercado de Seguros Médicos o uno que usted compra por su cuenta. Un plan para jubilados que forma parte de Medicare cuenta como Medicare. Las tarjetas de copago no se pueden usar con Medicare (incluido Medicare Advantage), Medicaid, TRICARE ni VA.
  • La mayoría de las tarjetas requieren inscribirse en el sitio web del fabricante, y muchas solo funcionan si su plan cubre el medicamento. Después, dé los datos de la tarjeta a la oficina de facturación de la clínica.
  • No deje ni cambie un medicamento sin hablar con su farmacéutico o su médico.